返回

讲师

食品及健康科学学系

联络方法

电邮: christytong@thei.edu.hk

电话: +852 2176 1815

TEACHING AREAS
  1. Pharmacology in Chinese Medicine
  2. Pharmaceutics in Chinese Medicine
  3. Operations and Management of Chinese Medicine Pharmacy
  • PhD in Pharmacy, The Chinese University of Hong Kong
  • Bachelor of Pharmacy (Hons) in Chinese Medicine, Hong Kong Baptist University

2022- present

 Lecturer, Faculty of Science and Technology, Technological and Higher Education Institute of Hong Kong
2021-2022 Technical officer, The University of Hong Kong
2015-2015 Chinese Medicine Ambassador (part-time), Department of Health
  1. Tong, C. W. S., Wu, W. K. K., Loong, H. H. F., Cho, W. C. S., & To, K. K. W. (2017). Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Lett, 405, 100-110. doi:10.1016/j.canlet.2017.07.023 
  2. Tong, C. W. S., Wu, M., Cho, W. C. S., & To, K. K. W. (2018). Recent Advances in the Treatment of Breast Cancer. Front Oncol, 8, 227. doi:10.3389/fonc.2018.00227 
  3. Tong, C. W. S., Wu, M. M. X., Yan, V. W., Cho, W. C. S., & To, K. K. W. (2020). Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells. Cancer Treat Res Commun, 25, 100229. doi:10.1016/j.ctarc.2020.100229
  4. Zhong, W. F.#, Tong, W. S.#, Zhou, S. S., Yip, K. M., Li, S. L., Zhao, Z. Z., . . . Chen, H. B. (2017). Qualitative and quantitative characterization of secondary metabolites and carbohydrates in Bai-Hu-Tang using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry and ultraperformance liquid chromatography coupled with photodiode array detector. J Food Drug Anal, 25(4), 946-959. doi:10.1016/j.jfda.2016.12.007 
  5. Li, H., Tong, C. W. S., Leung, Y., Wong, M. H., To, K. K., & Leung, K. S. (2017). Identification of Clinically Approved Drugs Indacaterol and Canagliflozin for Repurposing to Treat Epidermal Growth Factor Tyrosine Kinase Inhibitor-Resistant Lung Cancer. Front Oncol, 7, 288. doi:10.3389/fonc.2017.00288 
  6. To, K. K., Tong, W. S., & Fu, L. W. (2017). Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat. Lung Cancer, 103, 58-65. doi:10.1016/j.lungcan.2016.11.019 
  7. To, K. K., Tong, C. W. S., Wu, M., & Cho, W. C. (2018). MicroRNAs in the prognosis and therapy of colorectal cancer: From bench to bedside. World J Gastroenterol, 24(27), 2949-2973. doi:10.3748/wjg.v24.i27.2949 
  8. Wu, M., Tong, C. W. S., Yan, W., To, K. K. W., & Cho, W. C. S. (2019). The RNA Binding Protein HuR: A Promising Drug Target for Anticancer Therapy. Curr Cancer Drug Targets, 19(5), 382-399. doi:10.2174/1568009618666181031145953 
  9. To, K. K. W., Fong, W., Tong, C. W. S., Wu, M., Yan, W., & Cho, W. C. S. (2020). Advances in the discovery of microRNA-based anticancer therapeutics: latest tools and developments. Expert Opin Drug Discov, 15(1), 63-83. doi:10.1080/17460441.2020.1690449 
  10. Wu, M. M., Zhang, Z., Tong, C. W. S., Yan, V. W., Cho, W. C. S., & To, K. K. W. (2020). Repurposing of niclosamide as a STAT3 inhibitor to enhance the anticancer effect of chemotherapeutic drugs in treating colorectal cancer. Life Sci, 262, 118522. doi:10.1016/j.lfs.2020.118522# co-first authors